Context Therapeutics (CNTX) vs Kyntra Bio (KYNB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Kyntra Bio (KYNB) has outperformed Context Therapeutics (CNTX) over the past year, losing 47.7% versus a loss of 73.8%. Context Therapeutics is the larger company by market cap ($27.5 million vs $24.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CNTX | KYNB |
|---|---|---|
| Share price | $0.299 | $5.96 |
| Market cap | $27.47M | $24.13M |
| 1-day change | -4.35% | -1.32% |
| YTD return | -79.66% | -32.12% |
| 1-year return | -73.77% | -47.72% |
| 5-year return | — | -97.84% |
| EPS (TTM) | $-0.48 | $-7.46 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.62 | $11.65 |
| 52-week low | $0.295 | $5.62 |
| Distance from 52-week high | -91.74% | -48.84% |
| Analyst consensus | none | none |
| Avg. price target upside | +1247.83% | +565.60% |
| Average volume | 1.66M | 18.29K |
| Shares outstanding | 91.88M | 4.05M |
| Employees | 15 | 34 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KYNB has outperformed CNTX by 26.1 percentage points over the past year.
About Context Therapeutics
CNTX stock →Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
Healthcare · Biotechnology · 15 employees
About Kyntra Bio
KYNB stock →Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers.
Healthcare · Biotechnology · 34 employees
CNTX vs KYNB FAQ
Which is bigger, Context Therapeutics or Kyntra Bio?
Context Therapeutics (CNTX) is larger, with a market capitalization of $27.47M compared with $24.13M for Kyntra Bio (KYNB).
Which stock has performed better over the past year, CNTX or KYNB?
KYNB returned -47.72% over the past 12 months, compared with -73.77% for CNTX (price return, excluding dividends). Past performance does not predict future results.
Are Context Therapeutics and Kyntra Bio in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.